WITHDRAWN: Research on Traditional Chinese Medicine Syndrome Animal Models and Multi-omics Biomarkers in Type II Diabetes: A Review

Abstract

IntroductionDiabetes, a chronic metabolic disease marked by hyperglycemia, predominantly manifests as Type 2 Diabetes Mellitus (T2DM), representing over 90% of diabetes cases with intricate pathogenesis and varied pathological attributes. Drawing upon Traditional Chinese Medicine (TCM) principles, this article outlines the methodology and evaluation criteria for integrating TCM syndromes into animal models for T2DM while comprehensively examining T2DM pathogenic mechanisms and physiological characteristics from various omics perspectives to pinpoint essential biomarkers. MethodsResearchers conducted comprehensive searches using databases such as Web of Science, Google Scholar, Baidu Scholar and CNKI. Selection criteria were based on content relevance and publication date, resulting in the inclusion of 223 articles, including Chinese and English journal papers, master's and doctoral theses. This comprehensive review aims to highlight the importance of TCM in research related to T2DM, as well as its compatibility with modern technology, providing guidance for future development of targeted drugs and clinical treatment for T2DM. ResultsThis article, based on the fundamental theories of Traditional Chinese Medicine, summarized the methodology and evaluation criteria for constructing 6 types of T2DM animal models: Blood Stasis Syndrome, Kidney Yin Deficiency Syndrome, Spleen Deficiency Syndrome, Yang Deficiency Syndrome, Qi and Yin Deficiency Syndrome, and Yin and Yang Deficiency Syndrome. It comprehensively analyzed the latest research progress on the pathogenic mechanisms and physiological characteristics of T2DM from the perspectives of genomics, proteomics, transcriptomics, metabolomics, and gut microbiomics, providing crucial insights for the discovery of potential biomarkers for T2DM. DiscussionsThe broad use of multi-omics tech aids in T2DM pathogenesis understanding. For comprehensive insight, analyzing genes, proteins, metabolites and microbiota is vital. As a metabolic disorder, T2DM has a prolonged development process, necessitating the selection of different biomarkers for various stages of the disease progression and long-term monitoring of the overall changes in key biomarkers. The development of a “disease-syndrome” animal model is pivotal for the advancement of targeted drug therapies. The crux lies in the accuracy, repeatability, and stability of the model and its assessment criteria. Future investigations should focus on multi-omics analyses across diverse T2DM syndromes to facilitate personalized treatment strategies.